Erratum: Inhibition of human gamma delta T-cell antitumoral activity through HLA-G: Implications for immunotherapy of cancer (Cellular and Molecular Life Sciences DOI 10.1007/s00018-011-0632-7);Inhibition of human Vγ9Vδ2 T-cell antitumoral activity through HLA-G: Implications for immunotherapy of cancer

Cellular and Molecular Life Sciences

Volumn 68, Issue 20, 2011, Pages 3385-3399

  Lesport, Emilie ^a,b,d   Baudhuin, Jeremy ^a,b,d   Sousa, Sylvie ^a,b,d   Lemaoult, Joel ^a,b,d   Zamborlini, Alessia ^c,d   Rouas Freiss, Nathalie ^a,b,d   Carosella, Edgardo D ^a,b,d   Favier, Benoit ^a,b,d  

^a Inst Univ d'Hématologie   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c CNRS   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Cytotoxicity; HLA G; IFN ; ILT2 inhibitory receptor; T cell

Indexed keywords

GAMMA INTERFERON; HLA G ANTIGEN; IMMUNOGLOBULIN LIKE TRANSCRIPT 2 INHIBITORY RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-G ANTIGEN; IMMUNOGLOBULIN RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KIR2DL4 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LILRB1 PROTEIN, HUMAN; LILRB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MELANOMA CELL; T LYMPHOCYTE; TUMOR CELL LINE; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; WESTERN BLOTTING;

ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR2DL4; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80053131537     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0742-2     Document Type: Erratum

References (65)

1. AC Hayday 2000 [gamma][delta] cells: a right time and a right place for a conserved third way of protection Annu Rev Immunol 18 975 1026 10837080 10.1146/annurev.immunol.18.1.975 1:CAS:528:DC%2BD3cXjs1Gmt70%3D (Pubitemid 30365402)
2. AC Hayday 2009 Gammadelta T cells and the lymphoid stress-surveillance response Immunity 31 184 196 19699170 10.1016/j.immuni.2009.08.006 1:CAS:528:DC%2BD1MXhtFOgsL7N
3. A Thedrez C Sabourin J Gertner MC Devilder S Allain-Maillet JJ Fournie E Scotet M Bonneville 2007 Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 215 123 135 17291284 10.1111/j.1600-065X.2006.00468.x 1:CAS:528:DC%2BD2sXjsVKrtrc%3D (Pubitemid 46212235)
4. S Nedellec M Bonneville E Scotet 2010 Human Vgamma9Vdelta2 T cells: from signals to functions Semin Immunol 22 199 206 20447835 10.1016/j.smim.2010.04. 004 1:CAS:528:DC%2BC3cXovFCgsLc%3D
5. S Girlanda C Fortis D Belloni E Ferrero P Ticozzi C Sciorati M Tresoldi A Vicari T Spies V Groh F Caligaris-Cappio M Ferrarini 2005 MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes Cancer Res 65 7502 7508 16103105 10.1158/0008-5472.CAN-05-0731 1:CAS:528:DC%2BD2MXns1Wqs7o%3D (Pubitemid 41161286)
6. B Rincon-Orozco V Kunzmann P Wrobel D Kabelitz A Steinle T Herrmann 2005 Activation of V gamma 9V delta 2 T cells by NKG2D J Immunol 175 2144 2151 16081780 1:CAS:528:DC%2BD2MXntVSrtLg%3D (Pubitemid 41113819)
7. F Dieli N Gebbia F Poccia N Caccamo C Montesano F Fulfaro C Arcara MR Valerio S Meraviglia C Di Sano G Sireci A Salerno 2003 Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo Blood 102 2310 2311 12959943 10.1182/blood-2003-05-1655 1:CAS:528:DC%2BD3sXntlKrsbk%3D (Pubitemid 37122416)
8. M Wilhelm V Kunzmann S Eckstein P Reimer F Weissinger T Ruediger HP Tony 2003 Gammadelta T cells for immune therapy of patients with lymphoid malignancies Blood 102 200 206 12623838 10.1182/blood-2002-12-3665 1:CAS:528:DC%2BD3sXltFemurk%3D (Pubitemid 36759655)
9. F Dieli D Vermijlen F Fulfaro N Caccamo S Meraviglia G Cicero A Roberts S Buccheri M D'Asaro N Gebbia A Salerno M Eberl AC Hayday 2007 Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer Cancer Res 67 7450 7457 17671215 10.1158/0008-5472.CAN-07-0199 1:CAS:528:DC%2BD2sXosVemtLY%3D (Pubitemid 47206575)
10. H Kobayashi Y Tanaka J Yagi Y Osaka H Nakazawa T Uchiyama N Minato H Toma 2007 Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study Cancer Immunol Immunother 56 469 476 16850345 10.1007/s00262-006-0199-6 1:CAS:528:DC%2BD2sXht1yhsLg%3D (Pubitemid 46204533)
11. J Bennouna E Bompas EM Neidhardt F Rolland I Philip C Galea S Salot S Saiagh M Audrain M Rimbert S Lafaye-de Micheaux J Tiollier S Negrier 2008 Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma Cancer Immunol Immunother 57 1599 1609 18301889 10.1007/s00262-008-0491-8 1:CAS:528:DC%2BD1cXhtVejsbnK
12. Y Abe M Muto M Nieda Y Nakagawa A Nicol T Kaneko S Goto K Yokokawa K Suzuki 2009 Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma Exp Hematol 37 956 968 19409955 10.1016/j.exphem.2009.04.008 1:CAS:528:DC%2BD1MXos12ku70%3D
13. L Martinet R Poupot JJ Fournie 2009 Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies Immunol Lett 124 1 8 19465238 10.1016/j.imlet.2009.03.011 1:CAS:528:DC%2BD1MXmsVShtbw%3D
14. N Rouas-Freiss P Moreau C Menier J LeMaoult ED Carosella 2007 Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses Semin Cancer Biol 17 413 421 17881247 10.1016/j.semcancer.2007.07.003 1:CAS:528:DC%2BD2sXht12hsr%2FF (Pubitemid 350064561)
15. L Amiot S Ferrone H Grosse-Wilde B Seliger 2011 Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 68 417 431 21063893 10.1007/s00018-010-0583-4 1:CAS:528:DC%2BC3MXntVehtw%3D%3D
16. ED Carosella S Gregori N Rouas-Freiss J Lemaoult C Menier B Favier 2011 The role of HLA-G in immunity and hematopoiesis Cell Mol Life Sci 68 353 368 21116680 10.1007/s00018-010-0579-0 1:CAS:528:DC%2BC3MXntVehsQ%3D%3D
17. EM de Kruijf A Sajet JG van Nes R Natanov H Putter VT Smit GJ Liefers PJ van den Elsen CJ van de Velde PJ Kuppen 2010 HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients J Immunol 185 7452 7459 21057081 10.4049/jimmunol.1002629
18. B Favier J LeMaoult N Rouas-Freiss P Moreau C Menier ED Carosella 2007 Research on HLA-G: an update Tissue Antigens 69 207 211 17493143 10.1111/j.1399-0039.2006.00757.x 1:STN:280:DC%2BD2s3osFSmtg%3D%3D (Pubitemid 46696937)
19. ED Carosella B Favier N Rouas-Freiss P Moreau J Lemaoult 2008 Beyond the increasing complexity of the immunomodulatory HLA-G molecule Blood 111 4862 4870 18334671 10.1182/blood-2007-12-127662 1:CAS:528:DC%2BD1cXmtlaitbg%3D
20. ED Carosella P Moreau J Lemaoult N Rouas-Freiss 2008 HLA-G: from biology to clinical benefits Trends Immunol 29 125 132 18249584 10.1016/j.it.2007.11.005 1:CAS:528:DC%2BD1cXivVeis7Y%3D
21. N Rouas-Freiss RE Marchal M Kirszenbaum J Dausset ED Carosella 1997 The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A 94 5249 5254 9144223 10.1073/pnas.94.10.5249 1:CAS:528:DyaK2sXjtlensrY%3D (Pubitemid 27214769)
22. FA Le Gal B Riteau C Sedlik I Khalil-Daher C Menier J Dausset JG Guillet ED Carosella N Rouas-Freiss 1999 HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes Int Immunol 11 1351 1356 10421792 10.1093/intimm/11.8. 1351 1:CAS:528:DyaK1MXltFWltLY%3D (Pubitemid 29355674)
23. B Riteau N Rouas-Freiss C Menier P Paul J Dausset ED Carosella 2001 HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis J Immunol 166 5018 5026 11290782 1:CAS:528:DC%2BD3MXivVKms74%3D (Pubitemid 32280714)
24. H Sicard S Ingoure B Luciani C Serraz JJ Fournie M Bonneville J Tiollier F Romagne 2005 In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model J Immunol 175 5471 5480 16210655 1:CAS:528:DC%2BD2MXhtVyltr%2FO (Pubitemid 41456434)
25. N Rouas-Freiss S Bruel C Menier C Marcou P Moreau ED Carosella 2005 Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis Int J Cancer 117 114 122 15880415 10.1002/ijc.21151 1:CAS:528:DC%2BD2MXhtVaht7vI (Pubitemid 41262765)
26. S Le Rond C Azema I Krawice-Radanne A Durrbach C Guettier ED Carosella N Rouas-Freiss 2006 Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells J Immunol 176 3266 3276 16493088 1:CAS:528:DC%2BD28Xhs1eqsrc%3D
27. V Trichet C Benezech C Dousset MC Gesnel M Bonneville R Breathnach 2006 Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown J Immunol 177 6129 6136 17056540 1:CAS:528:DC%2BD28XhtFSns73F (Pubitemid 44628829)
28. A Thedrez C Harly A Morice S Salot M Bonneville E Scotet 2009 IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy J Immunol 182 3423 3431 19265120 10.4049/jimmunol.0803068 1:CAS:528:DC%2BD1MXis12isb4%3D
29. N Lila N Rouas-Freiss J Dausset A Carpentier ED Carosella 2001 Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism Proc Natl Acad Sci USA 98 12150 12155 11572934 10.1073/pnas.201407398 1:STN:280: DC%2BD3MrlvFajug%3D%3D (Pubitemid 32959842)
30. R Bahri F Hirsch A Josse N Rouas-Freiss N Bidere A Vasquez ED Carosella B Charpentier A Durrbach 2006 Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes J Immunol 176 1331 1339 16424159 1:CAS:528:DC%2BD28XlsFyisQ%3D%3D (Pubitemid 43134274)
31. T Gonen-Gross H Achdout R Gazit J Hanna S Mizrahi G Markel D Goldman-Wohl S Yagel V Horejsi O Levy M Baniyash O Mandelboim 2003 Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function J Immunol 171 1343 1351 12874224 1:CAS:528:DC%2BD3sXlsFylsLc%3D (Pubitemid 36900066)
32. V Ristich S Liang W Zhang J Wu A Horuzsko 2005 Tolerization of dendritic cells by HLA-G Eur J Immunol 35 1133 1142 15770701 10.1002/eji.200425741 1:CAS:528:DC%2BD2MXjslSgtLY%3D (Pubitemid 40542220)
33. V Ristich W Zhang S Liang A Horuzsko 2007 Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells Hum Immunol 68 264 271 17400062 10.1016/j.humimm.2006.11.008 1:CAS:528:DC%2BD2sXjslShsro%3D (Pubitemid 46497523)
34. R Apps L Gardner AM Sharkey N Holmes A Moffett 2007 A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1 Eur J Immunol 37 1924 1937 17549736 10.1002/eji.200737089 1:CAS:528:DC%2BD2sXnslyitLc%3D (Pubitemid 47065129)
35. C Solier M Aguerre-Girr F Lenfant A Campan A Berrebi V Rebmann H Grosse-Wilde P Le Bouteiller 2002 Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast Eur J Immunol 32 3576 3586 12516543 10.1002/1521-4141(200212)32:12<3576::AID-IMMU3576>3.0.CO;2-M 1:CAS:528:DC%2BD3sXjt1yh (Pubitemid 36024394)
36. P Contini M Ghio A Poggi G Filaci F Indiveri S Ferrone F Puppo 2003 Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation Eur J Immunol 33 125 134 12594841 10.1002/immu.200390015 1:CAS:528:DC%2BD3sXos1SmtQ%3D%3D (Pubitemid 36157650)
37. T Scholzen J Gerdes 2000 The Ki-67 protein: from the known and the unknown J Cell Physiol 182 311 322 10653597 10.1002/(SICI)1097-4652(200003)182: 3<311::AID-JCP1>3.0.CO;2-9 1:CAS:528:DC%2BD3cXot1Ggsg%3D%3D (Pubitemid 30054364)
38. SR Carding PJ Egan 2002 Gammadelta T cells: functional plasticity and heterogeneity Nat Rev Immunol 2 336 345 12033739 10.1038/nri797 1:CAS:528:DC%2BD38Xjsl2rsrY%3D (Pubitemid 37328756)
39. HH Takamatsu PA Kirkham RM Parkhouse 1997 A gamma delta T cell specific surface receptor (WC1) signaling G0/G1 cell cycle arrest Eur J Immunol 27 105 110 9022005 10.1002/eji.1830270116 1:CAS:528:DyaK2sXptVSltg%3D%3D (Pubitemid 27046065)
40. PA Kirkham HH Takamatsu RM Parkhouse 1997 Growth arrest of gammadelta T cells induced by monoclonal antibody against WC1 correlates with activation of multiple tyrosine phosphatases and dephosphorylation of MAP kinase erk2 Eur J Immunol 27 717 725 9079814 10.1002/eji.1830270321 1:CAS:528:DyaK2sXis1GjtL4%3D (Pubitemid 27110585)
41. PA Kirkham EW Lam HH Takamatsu RM Parkhouse 1998 Transcription factor E2F controls the reversible gamma delta T cell growth arrest mediated through WC1 J Immunol 161 1630 1636 9712024 1:CAS:528:DyaK1cXltlKns7s%3D (Pubitemid 28387577)
42. E Scotet S Nedellec MC Devilder S Allain M Bonneville 2008 Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk Front Biosci 13 6872 6885 18508701 10.2741/3195 1:CAS:528:DC%2BD1cXnsVOiurw%3D
43. E Morel T Bellon 2008 HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j J Immunol 181 2368 2381 18684926 1:CAS:528:DC%2BD1cXptlKqtbg%3D
44. B Favier J Lemaoult E Lesport ED Carosella 2010 ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse FASEB J 24 689 699 19841038 10.1096/fj.09-135194 1:CAS:528:DC%2BC3cXjtFagsLo%3D
45. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168 12538656 10.1084/jem.20021500 1:CAS:528: DC%2BD3sXmt1Sjtg%3D%3D (Pubitemid 36152311)
46. F Halary MA Peyrat E Champagne M Lopez-Botet A Moretta L Moretta H Vie JJ Fournie M Bonneville 1997 Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors Eur J Immunol 27 2812 2821 9394804 10.1002/eji.1830271111 1:CAS:528: DyaK2sXnt1Ojs7Y%3D (Pubitemid 27478348)
47. P Fisch E Meuer D Pende S Rothenfusser O Viale S Kock S Ferrone D Fradelizi G Klein L Moretta HG Rammensee T Boon P Coulie P van der Bruggen 1997 Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity Eur J Immunol 27 3368 3379 9464825 10.1002/eji.1830271236 1:CAS:528:DyaK1cXisF2ltw%3D%3D (Pubitemid 28018034)
48. F Poccia B Cipriani S Vendetti V Colizzi Y Poquet L Battistini M Lopez-Botet JJ Fournie ML Gougeon 1997 CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes J Immunol 159 6009 6017 9550399 1:CAS:528:DyaK1cXhtFCnsA%3D%3D (Pubitemid 127471537)
49. M Shiroishi K Tsumoto K Amano Y Shirakihara M Colonna VM Braud DS Allan A Makadzange S Rowland-Jones B Willcox EY Jones PA van der Merwe I Kumagai K Maenaka 2003 Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G Proc Natl Acad Sci U S A 100 8856 8861 12853576 10.1073/pnas.1431057100 1:CAS:528:DC%2BD3sXlvVyitLs%3D (Pubitemid 36899188)
50. N Anfossi JM Doisne MA Peyrat S Ugolini O Bonnaud D Bossy V Pitard P Merville JF Moreau JF Delfraissy J Dechanet-Merville M Bonneville A Venet E Vivier 2004 Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells J Immunol 173 7223 7229 15585844 1:CAS:528:DC%2BD2cXhtVCqur%2FP (Pubitemid 39628158)
51. MN Ince B Harnisch Z Xu SK Lee C Lange L Moretta M Lederman J Lieberman 2004 Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function Immunology 112 531 542 15270723 10.1046/j.1365-2567.2004.01907.x 1:CAS:528:DC%2BD2cXmslKgtbo%3D (Pubitemid 39061477)
52. BL Li A Lin XJ Zhang X Zhang JG Zhang Q Wang WJ Zhou HX Chen TJ Wang WH Yan 2009 Characterization of HLA-G expression in renal cell carcinoma Tissue Antigens 74 213 221 19531101 10.1111/j.1399-0039.2009.01302.x 1:CAS:528:DC%2BD1MXhtFGht7zF
53. G Singer V Rebmann YC Chen HT Liu SZ Ali J Reinsberg MT McMaster K Pfeiffer DW Chan E Wardelmann H Grosse-Wilde CC Cheng RJ Kurman M Shih Ie 2003 HLA-G is a potential tumor marker in malignant ascites Clin Cancer Res 9 4460 4464 14555519 1:CAS:528:DC%2BD3sXotVShtr4%3D (Pubitemid 37248404)
54. Y Sebti G Le Friec C Pangault F Gros B Drenou V Guilloux M Bernard T Lamy R Fauchet L Amiot 2003 Soluble HLA-G molecules are increased in lymphoproliferative disorders Hum Immunol 64 1093 1101 14602240 10.1016/j.humimm.2003.08.345 1:CAS:528:DC%2BD3sXos1Knsr4%3D (Pubitemid 37413719)
55. AY Yao HY Tang Y Wang MF Feng RL Zhou 2004 Inhibition of the activating signals in NK92 cells by recombinant GST-sHLA-G1a chain Cell Res 14 155 160 15115617 10.1038/sj.cr.7290215 1:CAS:528:DC%2BD2cXks1Kjs7w%3D
56. RG Roussev SC Ng CB Coulam 2007 Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G Am J Reprod Immunol 57 262 269 17362387 10.1111/j.1600-0897. 2007.00473.x 1:CAS:528:DC%2BD2sXltFWns7w%3D (Pubitemid 46394838)
57. E Lesport J Baudhuin J LeMaoult S Sousa C Doliger ED Carosella B Favier 2009 Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell Hum Immunol 70 1000 1005 19654030 10.1016/j.humimm.2009.07.019 1:CAS:528:DC%2BD1MXhsVajurjO
58. GM Park S Lee B Park E Kim J Shin K Cho K Ahn 2004 Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis Biochem Biophys Res Commun 313 606 611 14697234 10.1016/j.bbrc.2003.11.153 1:CAS:528:DC%2BD3sXhtVSjurfI (Pubitemid 38021873)
59. C Menier B Riteau ED Carosella N Rouas-Freiss 2002 MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal Int J Cancer 100 63 70 12115588 10.1002/ijc.10460 1:CAS:528:DC%2BD38XksVGntbw%3D (Pubitemid 34602066)
60. B Favier E Espinosa J Tabiasco C Dos Santos M Bonneville S Valitutti JJ Fournie 2003 Uncoupling between immunological synapse formation and functional outcome in human gamma delta T lymphocytes J Immunol 171 5027 5033 14607899 1:CAS:528:DC%2BD3sXoslyjtrY%3D (Pubitemid 37432783)
61. D Kabelitz D Wesch W He 2007 Perspectives of gammadelta T cells in tumor immunology Cancer Res 67 5 8 17210676 10.1158/0008-5472.CAN-06-3069 1:CAS:528:DC%2BD2sXisFWhsg%3D%3D (Pubitemid 46142752)
62. M Bonneville E Scotet 2006 Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors Curr Opin Immunol 18 539 546 16870417 10.1016/j.coi.2006.07.002 1:CAS:528:DC%2BD28XpsVKqu7k%3D (Pubitemid 44311448)
63. M Urosevic J Willers B Mueller W Kempf G Burg R Dummer 2002 HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas Blood 99 609 617 11781245 10.1182/blood.V99.2.609 1:CAS:528:DC%2BD38XmslGkuw%3D%3D (Pubitemid 34533099)
64. V Rebmann H Nuckel U Duhrsen H Grosse-Wilde 2007 HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications Semin Cancer Biol 17 430 435 17683947 10.1016/j.semcancer.2007.06.011 1:CAS:528:DC%2BD2sXht12hsrzN (Pubitemid 350052588)
65. K Dunker G Schlaf J Bukur WW Altermann D Handke B Seliger 2008 Expression and regulation of non-classical HLA-G in renal cell carcinoma Tissue Antigens 72 137 148 18721274 10.1111/j.1399-0039.2008.01090.x 1:CAS:528: DC%2BD1cXhtVGls7rI (Pubitemid 352009822)